German pharma giant Bayer records net losses of €3.6 billion in 2025

German pharmaceutical giant Bayer on Wednesday reported net losses of €3.6 billion ($4.2 billion) in 2025 amid litigation relating to the weedkiller Roundup.

The Leverkusen-based company saw sales drop by 2.2% to €45.6 billion, although adjusted sales were 1.1% up accounting for currency conversions.

In February, the agrochemical major announced it has reached a $7.25 billion class action settlement in the United States to resolve lawsuits relating to Roundup, which contains the chemical glyphosate.

Glyphosate has been deemed by the World Health Organization (WHO) "probably carcinogenic to humans," although Bayer disputes the claim.

The lawsuits were largely legacy issues from Bayer's 2018 acquisition of US competitor Monsanto.

Looking ahead, Bayer expects stable results in 2026. Adjusted for currency effects, the company has forecasted sales of €45 to €47 billion in 2026 and operating profit of €9.6 to €10.1 billion, which is roughly the same as in 2025.

At the turn of the year, Bayer had around 88,000 employees, around 5,000 fewer than a year earlier. In addition to weed killers and seeds, the company also sells medicines.